Why the study?
Blood pressure variability is associated with target organ damage, cardiovascular risk, and death, prompting an evaluation of its therapeutic implications in hypertension management.
Do antihypertensive medications, particularly calcium channel blockers, reduce blood pressure variability in hypertensive patients?
Do antihypertensive medications, particularly calcium channel blockers, reduce blood pressure variability in hypertensive patients?
Calcium channel blockers are the most effective antihypertensive class for reducing blood pressure variability, which is an independent risk factor for cardiovascular events and target organ damage.
May support preferring CCBs for BPV control; leaves open whether this improves outcomes in prospective trials.
Blood pressure (BP) is characterized by continuous dynamic and spontaneous oscillations occurring over lifetime and defining the so-called blood pressure variability (BPV). BPV has been associated with target organ damage, cardiovascular (CV) risk and death, suggesting the use of BPV as a new target in hypertension management in addition to mean BP values lowering. The purpose of the review is to focus on the therapeutic implications of BPV and summarize the effects of different drug classes on various types of BPV. Despite most first-line antihypertensive medications contribute to reduce both short and long term BPV, calcium channel blockers (CCBs) as monotherapy or fixed-combination therapy appear to be the most effective on BPV control. Further randomized interventional trials are needed to investigate which drug combinations are most appropriate according to patient CV risk stratification, in order to improve their CV outcomes.
No takes yet. Share an insight, caveat, or question.
Nardin et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: